These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16928786)

  • 1. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
    Uno T; Shimizu M; Sugawara K; Tateishi T
    Drug Metab Dispos; 2006 Nov; 34(11):1875-9. PubMed ID: 16928786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
    Shimizu M; Uno T; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 Sep; 62(3):372-6. PubMed ID: 16796706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
    Shon JH; Yoon YR; Hong WS; Nguyen PM; Lee SS; Choi YG; Cha IJ; Shin JG
    Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
    Yamada S; Yasui-Furukori N; Akamine Y; Kaneko S; Uno T
    Ther Drug Monit; 2009 Dec; 31(6):764-8. PubMed ID: 19855315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
    Yasui-Furukori N; Uno T; Sugawara K; Tateishi T
    Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of fexofenadine enantiomers in healthy subjects.
    Miura M; Uno T; Tateishi T; Suzuki T
    Chirality; 2007 Mar; 19(3):223-7. PubMed ID: 17230498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
    van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW
    J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
    Russell T; Stoltz M; Weir S
    Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
    Shimizu M; Uno T; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 May; 61(5):538-44. PubMed ID: 16669847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal interaction between itraconazole and cimetidine.
    Karyekar CS; Eddington ND; Briglia A; Gubbins PO; Dowling TC
    J Clin Pharmacol; 2004 Aug; 44(8):919-27. PubMed ID: 15286096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction.
    Jin MJ; Han HK
    J Food Sci; 2010 Apr; 75(3):H93-6. PubMed ID: 20492299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.
    Yamazaki A; Kumagai Y; Yamane N; Tozuka Z; Sugiyama Y; Fujita T; Yokota S; Maeda M
    J Clin Pharm Ther; 2010 Apr; 35(2):169-75. PubMed ID: 20456735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of fexofenadine enantiomers.
    Miura M; Uno T
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):69-74. PubMed ID: 19947891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of rifampin administration on the disposition of fexofenadine.
    Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD
    Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of St John's wort on the pharmacokinetics of fexofenadine.
    Wang Z; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2002 Jun; 71(6):414-20. PubMed ID: 12087344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
    Varis T; Kivistö KT; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters.
    Yasui-Furukori N; Saito M; Niioka T; Inoue Y; Sato Y; Kaneko S
    Ther Drug Monit; 2007 Feb; 29(1):45-8. PubMed ID: 17304149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides.
    Dresser GK; Kim RB; Bailey DG
    Clin Pharmacol Ther; 2005 Mar; 77(3):170-7. PubMed ID: 15735611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
    Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
    Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.